Global Anthrax Vaccines Market is valued at USD 569.7 Million in 2021 and expected to reach USD 1082.2 Million by 2028 with a CAGR of 8.39% over the forecast period.
Global Anthrax Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of anthrax, growing consumption of raw meat and rising immunization programmes of anthrax vaccines by government are major factors anticipated to drive the growth of the Global Anthrax Vaccines Market.
Anthrax infection is caused by the bacterium Bacillus anthracis and anthrax vaccines are used to prevent anthrax disease. The anthrax is deadly human disease also infect livestock animals as the bacterium lives in the soil and are eaten by animals like, sheep, goats, camel antelopes. Anthrax infection is spread by animals or contaminated animal products while it is not spread from person to person. Anthrax bacteria could be used in an attack against military personnel in the United States during a battle. The anthrax vaccine is best preventive measure taken against anthrax disease. The anthrax vaccine is generally given to people who are at higher risk of having anthrax infection such as laboratory workers and military people who work with Bacillus anthracis. The anthrax vaccine consists of 3 doses vaccine, followed by booster doses. Human anthrax vaccines were created by the Soviet Union in the last part of the 1930s and in the US and UK during the 1950s. The current antibody supported by the U.S. Food and Drug Administration (FDA) was planned during the 1960s.
The Covid-19 pandemic has also impacted the growth of the global anthrax vaccines market. As the Covid-19 cases were spiked , thus focus of healthcare industry principally moved to battle Covid-19 and other innovative work are required to be postponed. The anthrax vaccine immunization program has been slowed down due to supply chain disruptions and restrictions due to lockdown.
The global anthrax vaccines market is segmented on the basis of type, vaccine type, application, end-users and region & country level. On the basis of type, the global anthrax vaccines market is classified into live vaccines and cell free PA vaccines. The cell free PA vaccines further sub-divided into anthrax vaccine adsorbed (AVA) and anthrax vaccine precipitated (AVP). On the basis of vaccine type, the market is classified into human use and animal use. On the basis of end-users, the market is classified into hospitals, clinics, vaccination centres, and others.
The regions covered in global anthrax vaccines market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global anthrax vaccines is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of the key players in the global anthrax vaccines market are
On August 11th, 2020; The Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS) attempted of developing first oral anthrax vaccine for wildlife animals. The Benn Felix and the Cook Wildlife Lab team, in collaboration with VTPB researchers Dr. Allison Rice-Ficht and Dr. Thomas Ficht, attempting to create a formulation to deliver the vaccine orally, which would permit for potential distribution to wildlife.
On June 17th, 2019; Defence Research and Development Laboratory (DRDL), Mysore and Jawaharlal Nehru University (JNU) developed a new vaccine against anthrax. This vaccine gives protection from anthraxtoxin as well as its spores rather than the toxin alone. For the vaccine development together portions of two genes protective antigen protein and protein present in outer layer of spore are stitched. The protein produced was combination of the two proteins and was injected into mice. Scientists found that the vaccine can produce immune response against both spores and the toxin.
On March 20th, 2019; US based Emergent BioSolutions initiated a Phase III clinical trial of its anthrax vaccine AV7909 for post-exposure prophylaxis due to suspected or confirmed exposure to Bacillus anthracis bacteria. The new multi-focus, double-blind, randomized, equal gathering Phase III preliminary is intended to survey the part consistency, immunogenicity and wellbeing of AV7909 given intramuscularly to healthy grown-ups matured 18 to 65 years.
One of the major factors driving the growth of the global anthrax vaccines market is the increasing prevalence of anthrax. For instance, on May 13th, 2019, according to the first global survey of anthrax published in Nature Microbiology, estimated approximately 63 million livestock animals are susceptible to spore-forming bacterial disease and there are an estimated 20,000 to 100,000 cases of anthrax a year. Thus, increasing number of cases of anthrax disease is expected to drive the market of anthrax vaccines. In addition to that, second factor driving the growth of the global anthrax vaccines is growing consumption of raw meat. As undercooked or raw meat contain the Bacillus anthracis causative agent of anthrax. The consumption of such raw meat causes anthrax infection. Also, increased production of hair wools and hides of contaminated animals are also adding growth to the market. For example, according to The Organisation for Economic Co-operation Development (OECD) and the Food and Agricultural Organization (FAO) of the United Nations Agricultural Outlook 2021-2030, the global meat consumption per capita is anticipated to increase 0.3% p.a. to 35.4 kg by 2030.
Furthermore, increasing number of initiatives taken by government such as immunization programmes of anthrax vaccines are also supplementing the market growth. For example; in July 2020, to fight with the anthrax disease Anthrax Vaccine Research Program (AVRP) launched by The Centres for Disease Control and Prevention (CDC). With launch of this programme CDC studying the about next- generation and cost-effective anthrax vaccines which is boosting the growth of the global anthrax vaccines market. However, high cost associated with vaccine and lack of awareness may restrain the growth of the global anthrax vaccines market. In spite of that, increasing number of research and development activities in anthrax vaccines may offer more opportunities for the further growth of the global anthrax vaccines market.
North America is expected to dominate the global anthrax vaccines market due to increasing number of livestock animals, growing technological advancements in vaccine and presence of key players in this region. For instance; according to the first global survey of anthraxin North America, about 39 million livestock, primarily cattle, live in anthrax-endemic areas. In addition, increased adoption of anthrax vaccines by U.S military personnel to avoid getting infected through biological weapon is also fuelling the market growth. For example; on December 18th, 2018, Health Canada approved Emergent BioSolutions’ new anthrax vaccine. Moreover, presence of key players in this region are also boosting the growth of the global anthrax vaccines market. For instance; in August 2020, Elusys Therapeutics Inc. (Elusys) got endorsement from Health Canada for Anthim (obiltoxaximab for infusion) monoclonal immune response (mAb) anthrax antitoxin for the therapy of inhalation anthrax. It very well may be utilized in both grown-ups and paediatrics for post- exposure prophylaxis treatment.
Asia Pacific is expected to show fastest growth in the global anthrax vaccines market due to the anthrax disease outbreaks and improved health care infrastructure in this region. For instance; on June 17th, 2019, researchers from the Defence Research and Development Laboratory (DRDL), Mysore and Jawaharlal Nehru University (JNU) developed a single vaccine which provides immunity against both the toxin and its spores. This research further fuelling the market growth in the future in Asia Pacific region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 592.4 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 1245.6 Million|
|Tables, Charts & Figures:||175|
|Anthrax Vaccines Companies||Emergent BioSolutions, Merial, Tiankang, Zoetis, Pharm Athene, Merck, CAVAC, Colorado Serum, Bayer Sanidad Animal, Biogénesis-Bago, IVPM, Indian Immunologicals, JOVAC, Ceva Santé Animale, Prondil, Botswana Vaccine Institute and others.|
|Segments Covered||By Product, By Application, By End-Users|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|